CoChat

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

BACKGROUND: mutations present in more than 90% of cases. Daraxonrasib is an oral RAS(ON) multiselective, tri-complex inhibitor of the active guanosine triphosphate-bound state of mutant and wild-type RAS. METHODS: G12 and overall populations. Safety was also assessed. RESULTS: G12 population was 7.3 months with daraxonrasib and 3.5 months with chemotherapy, and that in the overall population was 7.2 months and 3.6 months, respectively; the hazard ratios were 0.45 and 0.49, respectively (P<0.001 for both comparisons). Adverse events that occurred after the start of treatment were reported in all the patients in the daraxonrasib group and in 97.7% of those in the chemotherapy group; the incidence of adverse events of grade 3 or higher was 61.8% and 69.6%, respectively. Treatment-related adverse events that led to treatment discontinuation occurred in 1.2% of the patients in the daraxonrasib group and in 11.2% of those in the chemotherapy group. CONCLUSIONS: Among patients with previously treated mPDAC, treatment with daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. (Funded by Revolution Medicines; RASolute 302 ClinicalTrials.gov number, NCT06625320.).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa2605555

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Research works printed but not linked: 1

  1. Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin 2026;76(1):e70043-e70043.41528114

Cited by

Items 101–200 of 226

Metadata

Authors
O’Reilly, E. M., Wainberg, Z. A., Hendifar, A. E., Borad, M. J., Pietrantonio, F., Pant, S., Hammel, P., Cremolini, C., Manji, G. A., Oberstein, P. E., Garrido-Laguna, I., Springfeld, C., Azad, N. S., Ueno, M., Chui, S. Y., Zhang, Y., Patel, H., Lee, Y., Salman, Z., & Wolpin, B. M.
Affiliations
  • Memorial Sloan Kettering Cancer Center, New York
  • University of California, Los Angeles (US)
  • Cedars-Sinai Medical Center (US)
  • Mayo Clinic in Arizona (US)
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
  • The University of Texas MD Anderson Cancer Center (US)
  • Université Paris-Saclay (FR)
  • University of Pisa (IT)
  • Columbia University Irving Medical Center (US)
  • NYU Langone Health (US)
  • Huntsman Cancer Institute, University of Utah, Salt Lake City
  • University Hospital Heidelberg (DE)
  • Sidney Kimmel Comprehensive Cancer Center (US)
  • Kanagawa Cancer Center (JP)
  • Revolution Medicines (United States) (US)
  • Dana-Farber Cancer Institute (US)
Venue
New England Journal of Medicine
Published
2026-07-23
Volume
395
Issue
4
Pages
325-337
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W7162952636
Cited by
147
References
30
Citations by year
2026: 147
FWCI
431.89
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Revolution Medicines
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords
daraxonrasib, metastatic pancreatic ductal adenocarcinoma, RAS inhibitors, previously treated patients, chemotherapy comparison, overall survival, progression-free survival, adverse events, treatment discontinuation
MeSH terms
Gain of Function Mutation, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Piperazines, Quality of Life, Time Factors, ras Proteins, Carcinoma, Pancreatic Ductal, Kaplan-Meier Estimate, Response Evaluation Criteria in Solid Tumors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.